AARD · Aardvark Therapeutics Inc. Common Stock
View on chartInsiders & Stakes
| Vickers Venture Fund VI Pte Ltd | ▼ Sell | Other | 2,050,902 Shares held | 2/14/2025 | View profile |
| Lee Tien-Li Chief Executive Officer | ▲ Buy | Open Market | 1,551,613 Shares held | 12/11/2025 | View profile |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 987,689 Shares held | 2/14/2025 | View profile |
| Decheng Capital Global Life Sciences Fund IV, L.P. | ▲ Buy | Open Market | 958,412 Shares held | 2/14/2025 | View profile |
| Chi Jeffrey | ▼ Sell | Other | 133,364 Shares held | 2/14/2025 | View profile |
| Sun Nelson See Remarks | ▼ Sell | Open Market | 35,475 Shares held | 9/11/2026 | View profile |
| Jones Bryan Chief Operating Officer | ▲ Buy | Option Exercise | 1,250 Shares held | 10/15/2025 | View profile |
Transaction History
| Sun Nelson | ▼ Sell | Open Market | 62,000 | $321K | 9/11/2026 |
| Sun Nelson | ▼ Sell | Open Market | 14,754 | $74K | 9/10/2026 |
| Sun Nelson | ▲ Buy | Open Market | 3,000 | $43K | 12/11/2025 |
| Lee Tien-Li | ▲ Buy | Open Market | 7,000 | $101K | 12/11/2025 |
| Lee Tien-Li | ▲ Buy | Option Exercise | 1,229 | $5K | 10/15/2025 |
| Jones Bryan | ▲ Buy | Option Exercise | 1,250 | $5K | 10/15/2025 |
| Lee Tien-Li | ▲ Buy | Open Market | 3,500 | $35K | 9/15/2025 |
| Lee Tien-Li | ▲ Buy | Open Market | 6,500 | $62K | 9/15/2025 |
| Lee Tien-Li | ▲ Buy | Open Market | 5,000 | $43K | 9/12/2025 |
| Lee Tien-Li | ▲ Buy | Open Market | 6,000 | $47K | 9/11/2025 |
| Lee Tien-Li | ▲ Buy | Open Market | 9,000 | $71K | 9/10/2025 |
| Sun Nelson | ▲ Buy | Open Market | 6,000 | $48K | 9/9/2025 |
| Lee Tien-Li | ▲ Buy | Option Exercise | 17,209 | $73K | 8/28/2025 |
| Lee Tien-Li | ▲ Buy | Open Market | 16,542 | $265K | 2/14/2025 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | ▲ Buy | Open Market | 625,000 | $10.0M | 2/14/2025 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | ▲ Buy | Open Market | 625,000 | $10.0M | 2/14/2025 |
| Cormorant Asset Management, LP | ▼ Sell | Other | 800,189 | — | 2/14/2025 |
| Lee Tien-Li | ▼ Sell | Other | 41,303 | — | 2/14/2025 |
| Vickers Venture Fund VI Pte Ltd | ▼ Sell | Other | 413,491 | — | 2/14/2025 |
| Vickers Venture Fund VI Pte Ltd | ▼ Sell | Other | 1,637,411 | — | 2/14/2025 |
| Chi Jeffrey | ▼ Sell | Other | 133,364 | — | 2/14/2025 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | ▼ Sell | Other | 333,412 | — | 2/14/2025 |
| Sun Nelson | ▼ Sell | Other | 7,001 | — | 2/14/2025 |
| Sun Nelson | ▲ Buy | Open Market | 10,000 | $160K | 2/14/2025 |
| Cormorant Asset Management, LP | ▲ Buy | Open Market | 187,500 | $3.0M | 2/14/2025 |
| Decheng Capital Global Life Sciences Fund IV, L.P. | ▼ Sell | Other | 2,333,887 | — | 2/14/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD)
RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD). RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.